Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
OTC: ACUT

Accustem Sciences Inc.

Healthcare | Biotechnology
$0.23 -0.02 (-9.53%) as of 2026-07-15 03:06 UTC
Volume135

Accustem Sciences Inc. (OTC: ACUT) is a biotechnology company trading at $0.23 (−9.5% today). Figures from SEC EDGAR and market feeds; updated 2026-07-15 03:06 UTC.

52-Week Range
Low $0.23High $2.33

What Accustem Sciences Inc. does

Ethos Technologies is a clinical-stage diagnostics company developing genomic tests to support cancer care decisions. The company is focused on commercializing two proprietary tests: MSC, a microRNA assay to help distinguish benign from malignant lung nodules, and StemPrintER, a gene assay to predict recurrence risk in early-stage breast cancer. MSC has been validated in prospective clinical cohorts and published in top-tier journals, while StemPrintER has been validated in multiple clinical studies including the TransATAC trial.

Summarized from Accustem Sciences Inc.’s SEC filings · Read the filing ↗

Key facts
Quote
Price$0.23
Change (1D)-0.02 (-9.53%)
Volume135 shares
52-week range$0.23 – $2.33
Returns
52-week return+0.0%
Price Chart
52-Week Range
Low $0.23High $2.33
Interactive chart available in terminalLive price charts with full OHLCV data, volume overlay, and technical indicators.
Open ACUT in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2025-06-16
Most recent filed transactions — June 2025:
  • 2025-06-16CERRONE GABRIELE MBUY400$440
  • 2025-06-16CERRONE GABRIELE MBUY2,000$2.0K
  • 2025-06-13CERRONE GABRIELE MBUY28,205$11.0K
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
No 13F filings reference ACUT in the last quarter.
Source: SEC EDGAR · Last checked 2026-07-15
Company news View all →
No qualifying company news in the archive. Full tape in the platform →
Questions this page answers

What does Accustem Sciences Inc. do?

Ethos Technologies is a clinical-stage diagnostics company developing genomic tests to support cancer care decisions.

What is ACUT's valuation?

ACUT trades at $0.23, as of 2026-07-15.

When did ACUT last file with the SEC?

Accustem Sciences Inc.'s most recent SEC filing on record is a 10-Q filed 2026-05-15. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-15 03:06 UTC. This page is also available as JSON at /api/data?ticker=ACUT and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ACUT and 3,500+ tickers.

Create a free account — keep ACUT
For your agent
GET /api/data?ticker=ACUT

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt